May 29, 2026
•
5 min read
40,000 attendees. 7,000 abstracts. Revolution's plenary is tomorrow morning. Lantheus got a $7B take-private offer from Curium. AbbVie landed a rare blood cancer approval. BridgeBio got Priority Review for a muscular dystrophy drug.
May 28, 2026
6 min read
ASCO abstracts are out. sac-TMT plus Keytruda versus Keytruda alone in first-line lung cancer: 65% lower risk of progression or death. ASCO opens tomorrow. Revolution's plenary is Saturday. The abstracts signal the most data-rich oncology meeting in years.
May 27, 2026
Curevo (shingles), LimmaTech (bacterial AMR), and Vaccine Company (Epstein-Barr virus). That's deals 8, 9, and 10 this year. Total 2026 M&A now exceeds $25B. ASCO opens tomorrow. Revolution's plenary is Saturday.
May 26, 2026
Baxfendy is the first new hypertension mechanism in two decades. Mineralys' rival has a December PDUFA. ASCO opens Thursday with Revolution's plenary on Saturday. Plus the device tariff report is overdue.
Revolution Medicines presents full Phase 3 pancreatic cancer data in a plenary session on Saturday. A new ADC was approved for triple-negative breast cancer. Gilead got the first-ever HDV treatment approved. And the EU locked in its supply chain law.
Retatrutide delivered 28.3% weight loss (70.3 lbs) at 80 weeks. Extension patients lost 30.3% at 104 weeks. Truist projects $12B to $19B in peak sales. Lilly also made its seventh acquisition of the year. ASCO is 9 days out.
Five CDER heads in one year. Fewer than half of senior FDA leaders from six months ago remain. Capital Alpha called it "the most damaging period in FDA history." Relay outpaced Novartis in rare disease. AbbVie locked Rinvoq generics out until 2037.
Sacituzumab tirumotecan improved both PFS and OS. Truist projects Revolution Medicines could be approved by September. Regeneron pivots after its LAG-3 miss. The FDA accepted a Factor XIa stroke prevention NDA. And a Trump ethics disclosure involves Lilly stock.
The Bundibugyo variant has no approved vaccines or therapeutics. 246 suspected cases and 80 deaths in the DRC. It has spread to Uganda. The FDA just lost its interim drug chief too. And Regeneron's oncology pipeline took another hit.
The Supreme Court maintained mail and telehealth access for mifepristone. The FDA approved Enhertu for early breast cancer with a Natera companion diagnostic. Anthropic partnered with the Gates Foundation. And China just gave itself new power over Western pharma.
Evonik raised prices 15% on pharma inputs. Strait of Hormuz shipping is down 90%. India's API exports are being rerouted at 350% higher air cargo costs. Biotech leaders want Pazdur as the next FDA chief. Gene therapy just got a safety scare.
He resigned Tuesday over e-cigarettes. Diamantas is acting. Three Senate-confirmed health positions are now empty. The search is underway. Here's what it means for every filing in the pipeline.
Stay on the Cutting Edge of Biotech, MedTech, and Pharma.
